Cost estimation methods in health economic evaluation;Methoden der kostenbestimmung in der gesundheitsökonomischen evaluation

Gesundheitsokonomie und Qualitatsmanagement

Volumn 15, Issue 5, 2010, Pages 251-259

  Krauth, C ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

cost; cost estimation; cost valuation; evaluation; health economics

Indexed keywords

COST EFFECTIVENESS ANALYSIS; HEALTH ECONOMICS; MORBIDITY; MORTALITY; REVIEW;

EID: 78049379490     PISSN: 14322625     EISSN: 14394049     Source Type: Journal    
DOI: 10.1055/s-0029-1245680     Document Type: Review

References (46)

1. Gold M R. Russell L B. Siegel J E. Cost-effectiveness in health and medicine. New York Oxford University Press 1996
2. Johannesson M. Theory and methods of economic evaluation of health care. 1996 Dordrecht Kluwer Academic Publishers
3. Drummond M F., Sculpher M J., Torrance G W. et al. Methods for the economic evaluation of health care programmes. 3 rd edition Oxford Oxford University Press 2005
4. Drummond M F. McGuire A E. Economic evaluation in health care: merging theory with practice. Oxford Oxford University Press 2001
5. AG Reha-Ökonomie, Hessel F Kohlmann T Krauth C et al Gesundheitsökonomische Evaluation: Teil 1; Prinzipien und Empfehlungen für die Leistungserfassung. In: Verband Deutscher Rentenversicherungsträger (Hrsg) Förderschwerpunkt Rehabilitationswissenschaften: Empfehlungen der Arbeitsgruppen Generische Methoden, Routinedaten und Reha-Ökonomie (DRV-Schriften; Band 16). Frankfurt VDR 1999 103-193
6. Schöffski O der Schulenburg J M. Gesundheitsökonomische Evaluation. 3. Aufl Berlin Springer 2008
7. Weinstein M C., Siegel J E., Gold M R. et al. Recommendations of the Panel on Cost-Effectiveness in Health and Medicine. JAMA 1996 276 (15) 1253-1258
8. Canadian Agency for Drugs and Technologies in Health. Guidelines for the economic evaluation of health technologies. Canada Ottawa CADTH 2006
9. der Schulenburg J M. von, Greiner W von, Jost F et al. Deutsche Empfehlungen zur gesundheitsökonomischen Evaluation: 3. Fassung des Hannoveraner Konsens. Gesundheitsökonomie & Qualitätsmanagement 2007 12 (5) 285-290
10. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Allgemeine Methoden zur Bewertung von Verhältnissen zwischen Nutzen und Kosten. Version 1.0 vom 12. 10.2009. http://:iqwig.de/ index735.html
11. Drummond M McGuire A (Hrsg) Costing in economic evaluations. Oxford Oxford University Press 2001 68-93
12. Gold M R. Siegel J E. Russell L B. et al (Hrsg) Estimating costs in cost-effectiveness analysis. New York Oxford University Press 1996 176-213
13. Gold M R. Siegel J E. Russell L B. et al (Hrsg) Framing and designing the cost-effectiveness analysis. New York Oxford University Press 1996 54-81
14. Zentner A, Busse R. Internationale Standards der Kosten-Nutzen-Bewertung. Gesundheitsökonomie & Qualitätsmanagement 2006 11 368-373
15. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Arbeitspapier Kostenbestimmung. Version 1.0 vom 12.10.2009. http://:iqwig.de/index.736.html
16. Canadian Coordinating Office for Health Technology Assessment. Guidelines for economic evaluation of pharmaceuticals. Canada Ottawa CCOHTA 1997
17. Gold M R. Siegel J E. Russell L B. et al (Hrsg) Theoretical foundations of cost-effectiveness analysis. New York Oxford University Press 1996 25-53
18. Garber A M., Phelps C E. Economic foundations of cost-effectiveness analysis. J Health Econ 1997 16 (1) 1-31
19. Meltzer D. Accounting for future costs in medical cost-effectiveness analysis. J Health Econ 1997 16 (1) 33-64
20. Weinstein M C., Manning W G. Theoretical issues in cost-effectiveness analysis. J Health Econ 1997 16 (1) 121-128
21. Nyman J A. Should the consumption of survivors be included as a cost in cost-utility analysis? Health Econ 2004 13 417-427
22. Johannesson M. Avoiding double-counting in pharmacoeconomic studies. Pharmacoeconomics 1997 11 (5) 385-388
23. Brouwer W BF, Koopmanschap M A., Rutten F FH. Productivity costs measurement through quality of life: a response to the recommendation of the Washington Panel. Health Econ 1997 6 (3) 253-259
24. Drummond M McGuire A (Hrsg) The role and estimation of productivity costs in economic evaluation. Oxford Oxford University Press 2001 94-112
25. Brouwer W BF, Koopmanschap M A., Rutten F FH. Productivity costs in cost-effectiveness analysis: numerator or denominator; a further discussion. Health Econ 1997 6 (5) 511-514
26. Sculpher M J., OBrien B J. Income effects of reduced health and health effects of reduced income: implications for health-state valuation. Med Decis Making 2000 20 (2) 207-215
27. Torrance G W., Feeny D H., Furlong W J. et al. Multiattribute utility function for a comprehensive health status classification system: Health Utilities Index Mark 2. Med Care 1996 34 (7) 702-722
28. Oostenbrink J B., Koopmanschap M A., Rutten F F. Standardisation of costs: the Dutch Manual for Costing in economic evaluations. Pharmacoeconomics 2002 20 (7) 443-454
29. Johnston K, Buxton M J., Jones D R. et al. Assessing the costs of healthcare technologies in clinical trials. Health Technol Assess 1999 3 (6) 1-76
30. Krauth C, Hessel F, Hansmeier T et al. Empirische Bewertungssätze in der gesundheitsökonomischen Evaluation: ein Vorschlag der AG Methoden der gesundheitsökonomischen Evaluation (AG MEG). Gesundheitswesen 2005 67 736-746
31. Garrison L P., Mansley E C., Abott T A. et al. Good research practices for measuring drug costs in cost effective analyses: a report of the ISPOR Drug Cost Task Force; part II; a societal perspective [Draft]. ISPOR 2008 http://www.ispor.org/councils/documents/ISPOR-Report-Good-Practices- SocietalPerspective.pdf
32. Koopmanschap M A., Rutten F FH, Inefeld B M. et al. The friction cost method for measuring indirect costs of disease. J Health Econ 1995 14 171-189
33. Koopmanschap M A., Inefeld B M. van. Towards a new approach for estimating indirect costs of disease. Soc Sci Med 1992 34 (9) 1005-1010
34. Johannesson M van, Karlsson G. The friction cost method: a comment. J Health Econ 1997 16 249-255
35. Koopmanschap M A., Rutten F FH, Ineveld B M. et al. Reply to Johannesons and Karlssons comment. J Health Econ 1997 16 257-259
36. Liljas B van. How to calculate indirect costs in economic evaluations. Pharmacoeconomics 1998 13 (1 Pt 1) 1-7
37. Gold M R. Siegel J E. Russell L B. et al (Hrsg) Time preference. New York Oxford University Press 1996 214-264
38. Drummond M F. McGuire A E. (Hrsg) Discounting in economic evaluation. Oxford Oxford University Press 2001 236-255
39. Barro R J., Martin X S. World real interest rates. NBER Macroeconomics Annual 1990 5 15-61
40. Desroche B, Francis M. World real interest rates: a global savings and investment perspective. Bank of Canada Ottawa 2007 Band 2007 16 Working Paper http://www.bank-banque-canada.ca/en/res/wp/2007/wp07-16.pdf
41. Krauth C, Dintsios C M., Brandes I et al. Die Perspektive der Gesetzlichen Krankenversicherung in der gesundheitsökonomischen Evaluation. Zeitschrift für die gesamte Versicherungswissenschaft 2005 94 215-256
42. Commonwealth Department of Health and Ageing. Guidelines for the pharmaceutical industry on preparation of submissions to the Pharmaceutical Benefits Advisory Committee. Commonwealth DHA Canberra 2002
43. Canadian Coordinating Office for Health Technology Assessment. A guidance document for the costing process. Canadian Coordinating Office for Health Technology Assessment Ottawa 1996
44. Jacobs P, Roos N P. Standard cost lists for healthcare in Canada: issues in validity and inter-provincial consolidation. Pharmacoeconomics 1999 15 (6) 551-560
45. Oostenbrink J B., Bouwmans C AM, Koopmanschap M A. et al. Handleiding voor kostenonderzoek: methoden en standaard kostprijzen voor economische evaluaties in gezondheidszorg. College voor zorgverzekeringen Diemen 2004 http://www.cvz.nl/resources/feo-handleiding-kostenonderzoek2004-tcm28-17013.pdf
46. Braun S, Prenzler A, Mittendorf T et al. Bewertung von Ressourcenverbräuchen im deutschen Gesundheitswesen aus Sicht der Gesetzlichen Krankenversicherung. Gesundheitswesen 2009 71 19-23